Phase III · Positive results published · US-approved
SPOTLIGHT — Targeted zolbetuximab therapy in advanced gastric cancer
A Phase 3 Study of Zolbetuximab Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin 18.2-Positive, HER2-Negative Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (SPOTLIGHT)
Not an individual treatment recommendation. This page summarizes a study with published results; suitability, approval, and access require clinician judgment.
For patients
Patient question
In advanced gastric cancer, can adding zolbetuximab to chemotherapy prolong survival?
SPOTLIGHT enrolled people with not removable by surgery or metastatic gastric or gastroesophageal-junction cancer.
Participants had tumors with a defined level of CLDN18.2 protein and were HER2-negative.
They received standard mFOLFOX6 chemotherapy with either targeted zolbetuximab or placebo, to assess whether the new treatment delayed progression and prolonged survival.
Key result
Both time to progression and overall survival were meaningfully longer with added zolbetuximab than with chemotherapy alone.
Median progression-free survival: 10.6 versus 8.7 months.
Median overall survival: 18.2 versus 15.5 months.
These are group medians from the trial; they do not mean every person will live the same length of time.
Median progression-free survival
Median overall survival was also 18.2 versus 15.5 months. CLDN18.2 positivity used a defined immunohistochemistry threshold in the trial; a report saying only “positive” is not enough.
What are the side effects of treatment?
Adding zolbetuximab can make nausea, vomiting, and loss of appetite more common.
Preventive anti-nausea medicines before and during treatment, plus monitoring of fluid intake and nutrition, are therefore important.
Why does this result matter?
In some gastric cancers, tumor cells carry the surface protein CLDN18.2. Zolbetuximab is an antibody that targets this protein.
SPOTLIGHT showed that, in eligible patients, adding zolbetuximab to chemotherapy improved both disease control and overall survival.
Treatment selection in advanced gastric cancer therefore increasingly includes CLDN18.2 status alongside biomarkers such as HER2.
What did this study not prove?
It did not show the same benefit in CLDN18.2-negative tumors.
It did not study benefit in early operable gastric cancer.
It did not directly show superiority over other targeted drugs or immunotherapy combinations.
It did not prove the same effect in every patient or that treatment eliminates disease completely.
Which patients does this study cover?
Patients enrolled
- People with not removable by surgery locally advanced or metastatic gastric or gastroesophageal-junction adenocarcinoma
- People whose tumors are HER2-negative
- People who meet the trial’s CLDN18.2 positivity threshold
- People who have not yet received systemic therapy for advanced disease
Who cannot directly use these results?
- People who do not meet CLDN18.2 positivity criteria
- People with HER2-positive gastric cancer
- People with early-stage gastric cancer that can still be removed surgically
Eligibility depends on a defined CLDN18.2 immunohistochemistry threshold and HER2-negativity; a report that merely says “positive” is not enough.
Is this standard care today?
Zolbetuximab received FDA approval in the US on 18 October 2024 for use with chemotherapy in eligible CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal-junction adenocarcinoma.
It is one approved option in that group. Suitability still depends on molecular features and other available treatments.
Is this available in Türkiye?
Türkiye licensing, conditions of use for this indication, reimbursement, and current access must be verified separately.
Approval in the US or Europe does not mean automatic SGK coverage in Türkiye.
Scientific study details
- Study name
- SPOTLIGHT
- Clinical trial number
- NCT03504397
- Study type
- Phase III
- Recruitment (registry)
- Completed; results published
- Disease studied
- Previously untreated for advanced disease; CLDN18.2-positive and HER2-negative; unresectable locally advanced or metastatic gastric/GEJ adenocarcinoma (n=565; 283/282)
- Investigational treatment
- Zolbetuximab + mFOLFOX6
- Comparator approach
- Placebo + mFOLFOX6
- Primary endpoint
- Progression-free survival by independent central review (PFS)
- Publication status
- Peer-reviewed Lancet 2023 phase III results (DOI 10.1016/S0140-6736(23)00620-7).
- Approval status for the approach studied in this trial
- FDA approval — 18 October 2024 (US). Zolbetuximab-clzb (Vyloy) + fluoropyrimidine/platinum chemotherapy; CLDN18.2-positive, HER2-negative unresectable locally advanced or metastatic gastric/GEJ. Türkiye license/SGK separate.
- Results status
- Results disclosed / being followed
For information only. A treatment studied in a clinical trial should not be treated as standard care until results and relevant approvals are assessed.
Landmark Atlas
If this study changed the standard of care, its primary home is the Atlas: